Last reviewed · How we verify
NCT04564664
High-flow Oxygen Therapy During Exercise in Idiopathic Pulmonary Fibrosis
NA trial testing Oxygen in Idiopathic Pulmonary Fibrosis in 10 participants. Completed in 30 March 2021.
30 December 2020
Quick facts
| Lead sponsor | Parc de Salut Mar |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 March 2019 |
| Primary completion | 30 December 2020 |
| Estimated completion | 30 March 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Oxygen — full drug profile →
Conditions studied
- Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →
Sponsor
Parc de Salut Mar — full company profile →
Who can join
Adults 18 to 85, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objectives: 1. To evaluate endurance time during cardiopulmonary exercise test (CPET) performance comparing standard oxygen therapy to high-flow nasal cannula (HFNC) oxygen therapy in subjects with idiopathic pulmonary fibrosis (IPF) with exertional desaturation. 2. To assess oxygenation level (peripheral and muscular) as well as dyspnea and fatigue during exercise in IPF subjects with exertional desaturation using oxygen supplementation with HFNC compared with standard oxygen supplementation. Method: multicenter crossover clinical trial. Patients with IPF presenting oxygen desaturation during the six-minute walking test (6MWT) (SpO2 mean ≤ 85%) will be included consecutively . Each subject evaluated will perform initially an incremental CPET to evaluate the patient's maximum exercise capacity. Supplemental oxygen will be applied to maintain SpO2 \>85% with a Venturi mask. Maximum exercise capacity and the appropriate final oxygen inspiratory fraction (FiO2) needed for the following tests will be determined. Posteriorly each patient will perform two constant load CPET (at 75% of the maximum workload achieved with the incremental CPET); one with standard oxygen therapy and the other one with HFNC oxygen therapy. Endurance time, dyspnea and leg fatigue and oxygen saturation (peripheral and muscular) will be recorded. Evaluation measures: Endurance time, dyspnea and leg fatigue (Borg scale), and oxygen saturation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial.
Badenes-Bonet D, Cejudo P, Rodó-Pin A, Martín-Ontiyuelo C, et al · · 2021 · cited 16× · PMID 34749699 · DOI 10.1186/s12890-021-01727-9
Verify or expand the search:
- PubMed search for NCT04564664
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oxygen
Trials testing the same drug.
- NCT06327373 — A Feasibility Study of Supplemental Oxygen to Improve Pulmonary Hypertension in People With Intradialytic Hypoxemia · Phase 1, PHASE2 · not yet recruiting
- NCT07464730 — Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult · NA · not yet recruiting
- NCT06498908 — Intracervical Balloon Placement With Nitrous Oxide Administration · Phase 3 · withdrawn
- NCT07245628 — A Trial of Self-Adjusted Nitrous Versus Placebo During Office Vasectomy · EARLY_PHASE1 · recruiting
- NCT07369232 — Cerebral Hemodynamic Effects of Oxygen and Antioxidants (CHEOXANT) · NA · recruiting
Other recruiting trials for Idiopathic Pulmonary Fibrosis
Currently open trials in the same condition.
- NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
- NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
- NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
- NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
- NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting
Other Parc de Salut Mar trials
Trials by the same sponsor.
- NCT06163235 — Efficacy of a Mobile Application and Semi-attendance Program in Bariatric Surgery · NA · not yet recruiting
- NCT07223450 — A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling · Phase 1 · completed
- NCT07504913 — Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 · recruiting
- NCT06806072 — BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY · NA · not yet recruiting
- NCT04084795 — Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04564664 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Parc de Salut Mar
- Last refreshed: 13 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04564664.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing